Dupixent Was Supposed to Heal Their Skin.For Some, It May Have Caused Cancer.
Studies show Dupixent users face a 4× higher risk of developing cutaneous T-cell lymphoma (CTCL). The FDA is investigating. Sanofi and Regeneron have paid $14 billion in sales—while the label contains zero cancer warnings.
Now, families are getting answers. And pursuing justice.
GET YOUR FREE CASE REVIEW
Do You Qualify?
✓ You may have a case if:
You used Dupixent for:
- Atopic Dermatitis (Eczema)
- Moderate-to-Severe Asthma
- Chronic Sinusitis with Nasal Polyps
- Eosinophilic Esophagitis
- Prurigo Nodularis
- COPD
- Chronic Spontaneous Urticaria
AND were diagnosed with:
- Cutaneous T-Cell Lymphoma (CTCL)
- Mycosis Fungoides
- Sézary Syndrome
- Peripheral T-Cell Lymphoma
- T-Cell Non-Hodgkin Lymphoma
- NK-Cell Lymphoma
- Other T-Cell Malignancies
Exposed Families Are Fighting Back
In October 2025, the first Dupixent wrongful death lawsuit was filed in Tennessee. Cynthia Marie Hyde began Dupixent injections in June 2024 for atopic dermatitis. Four months later, she died of peripheral T-cell lymphoma.
The litigation is growing:
- First wrongful death lawsuit filed October 2025
- Second major filing December 2025 in Georgia federal court
- FDA formally acknowledged cancer signal in March 2025
Your case deserves to be heard too.
She Just Wanted Relief From Her Eczema.Nobody Warned Her About Cancer.
Sarah had battled severe eczema since childhood. The constant itching kept her awake at night. When Dupixent was approved, her dermatologist called it a breakthrough. Within weeks, her skin cleared up. She finally felt normal.
But a year later, the rashes returned—different this time. Darker patches. Stubborn plaques that wouldn’t respond to treatment.
When her doctor finally ordered a biopsy, the diagnosis wasn’t eczema. It was cutaneous T-cell lymphoma—a rare cancer that often mimics the very condition Dupixent was supposed to treat.
“I thought I was getting better. Nobody told me my ‘eczema’ might actually be cancer—or that Dupixent could be hiding it.”
"They Kept Telling Me It Was Just Bad Eczema"
Michael, 52, used Dupixent for two years for atopic dermatitis. His symptoms improved dramatically at first. Then new patches appeared—thicker, darker, in places he’d never had eczema before.
Three dermatologists told him it was a “flare-up.” They increased his Dupixent dose.
It took 18 months and a fourth opinion before a biopsy revealed mycosis fungoides—the most common form of CTCL. By then, the cancer had progressed to Stage IIB.
“The cruelest part? CTCL looks exactly like severe eczema. Dupixent made me feel better while the cancer grew. Nobody ever mentioned that risk.”
The Science Is Clear
4.1× higher risk of CTCL in Dupixent users (2024 JAAD study)
4.59× higher relative risk confirmed in independent TriNetX analysis
14× higher risk for patients treated 16+ weeks (2025 European Respiratory Journal)
30× higher reporting ratio for CTCL vs. all other medications in FDA database
300+ adverse event reports of lymphoma submitted to FDA
1 million+ patients treated with Dupixent globally
$14.15 billion in 2024 sales—with ZERO cancer warnings on the label
March 2025: FDA adds Dupixent to “Potential Signals of Serious Risks” list
“In our experience representing patients harmed by pharmaceutical products, we’ve observed that companies often prioritize profits over patient safety. When a drug generates $14 billion in annual sales while lacking basic cancer warnings supported by peer-reviewed science, families deserve answers—and accountability.”
— Paul Danziger, Danziger & De Llano, LLP
Time Is Running Out
The laww limits how long you have to file. If you were recently diagnosed—or recently learned about the connection between Dupixent and cancer—your window may be closing.
Don’t wait to find out if you qualify.
Your family deserves answers.
Get Your Free Case Review
We Promise:
✓ NO FEES unless we win
✓ 100% Confidential
✓ You pay NOTHING upfront
✓ We handle everything
Or call now to 1-(855) 557-8007
This is attorney advertising. Prior results do not guarantee similar outcomes. Free consultation. Stories on this page are based on publicly reported cases and may be illustrative composites; they do not represent specific clients of this firm.